Vertex Pharmaceuticals Incorporated / Alios BioPharma, Inc.
2011 · Licensing/Option · $1.5B · Complete
Announcement Sentiment
50
Neutral / mixed
Vertex licensed two nucleotide analogues (ALS-2200/VX-135 and ALS-2158) from Alios for $60M upfront, up to $715M in R&D milestones, up to $750M in sales milestones, plus tiered royalties — total deal up to ~$1.5B. Strategic counter to Pharmasset HCV nucleotide platform.
Did it work? Outcome assessment
Strategic verdict
Failed to Achieve
Financial impact
Impaired/Written Down
Pipeline outcome
Assets Terminated
Assessment window: 5yr post-close.
Key facts
AnnouncedJun 08, 2011
ClosedJul 01, 2011
Deal value$1.5B
Deal typeLicensing/Option
Therapeutic areaChronic hepatitis C virus infection
IndicationsChronic hepatitis C virus infection
Key assetsALS-2200 (VX-135) and ALS-2158 nucleotide analogues